Foghorn Therapeutics Inc. Stock price

Equities

FHTX

US3441741077

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
6.28 USD +3.46% Intraday chart for Foghorn Therapeutics Inc. -3.24% -2.64%
Sales 2024 * 35.28M Sales 2025 * 37.33M Capitalization 267M
Net income 2024 * -247M Net income 2025 * -221M EV / Sales 2024 * 4.85 x
Net cash position 2024 * 96.34M Net cash position 2025 * 227M EV / Sales 2025 * 1.07 x
P/E ratio 2024 *
-1.56 x
P/E ratio 2025 *
-2.46 x
Employees 116
Yield 2024 *
-
Yield 2025 *
-
Free-Float 74.26%
More Fundamentals * Assessed data
Dynamic Chart
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Foghorn Therapeutics Inc. to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909 CI
Eli Lilly: Foghorn's anti-tumor drug selected for clinical development CF
Foghorn Shares Rally as Eli Lilly Plans Clinical Program With Oncology Product DJ
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor CI
Foghorn Therapeutics Inc. Appoints Stephen J. Dipalma Interim Chief Financial Officer, Effective January 16, 2024 CI
Foghorn Therapeutics Inc. Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024 CI
Prime Medicine Names Foghorn Therapeutics' CFO to be its New Finance Chief MT
Foghorn Therapeutics Says CFO is Leaving; Shares Fall After-Hours MT
Foghorn Therapeutics Inc. Announces Resignation of Allan Reine as Chief Financial Officer, Effective January 16, 2024 CI
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from NASDAQ Biotechnology Index CI
Morgan Stanley Adjusts Price Target on Foghorn Therapeutics to $6 From $10, Maintains Equalweight Rating MT
Foghorn Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Foghorn Therapeutics Inc. to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference CI
Foghorn Therapeutics Begins Phase 1 Combination Study of FHD-286 to Treat AML MT
More news
1 day+3.46%
1 week-3.24%
Current month-18.76%
1 month-12.78%
3 months-5.85%
6 months+4.84%
Current year-2.64%
More quotes
1 week
5.85
Extreme 5.85
6.72
1 month
5.78
Extreme 5.7817
8.44
Current year
2.70
Extreme 2.7
8.44
1 year
2.70
Extreme 2.7
9.97
3 years
2.70
Extreme 2.7
24.34
5 years
2.70
Extreme 2.7
28.27
10 years
2.70
Extreme 2.7
28.27
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 17-04-30
Founder 63 15-09-30
Director of Finance/CFO 66 Jan. 15
Members of the board TitleAgeSince
Director/Board Member 60 17-06-30
Founder 63 15-09-30
Director/Board Member 69 22-08-15
More insiders
Date Price Change Volume
24-03-27 6.28 +3.46% 55,155
24-03-26 6.07 +2.19% 42,901
24-03-25 5.94 -6.60% 99,912
24-03-22 6.36 -3.20% 92,235
24-03-21 6.57 +1.23% 67,804

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company's Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The Company is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. It is also developing FHD-609, a targeted protein degrader, and which is evaluating in a Phase I study in synovial sarcoma.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.28 USD
Average target price
13.75 USD
Spread / Average Target
+118.95%
Consensus
  1. Stock
  2. Equities
  3. Stock Foghorn Therapeutics Inc. - Nasdaq